Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Norlase

Explore full profile

Emerging global ophthalmic medical device company developing next-generation laser solutions for the treatment of retina and glaucoma disease

Ballerup, DenmarkFounded 2014Health Tech & Medtech
Valuation $50–100M Last recorded · 2021
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Norlase and the history behind them.

About Norlase

Norlase is a pioneering startup in the medical technology sector, specializing in the production of portable laser devices for ophthalmic treatments. The company's flagship products include ECHO, LION, and LEAF, each offering unique features that enhance treatment flexibility and practice efficiency.

ECHO is the world's first truly portable pattern laser, combining Norlase's ultra-compact laser engine with industry-first MEMS pattern technology. This integrated design eliminates the need for bulky tables and cumbersome cables, offering true portability.

LION is an indirect ophthalmoscope integrated with a green laser source, creating a first-of-its-kind treatment device. It is battery-powered, utilizes a wireless user interface, and has voice control of parameters, providing the ultimate in portability and treatment flexibility.

LEAF is a unique green laser photocoagulator that attaches directly to an existing slit lamp, eliminating the need for external fibers, carts, or counter space.

Norlase's clients are primarily healthcare providers in the ophthalmology sector. The company operates in the medical technology market, a sector known for its high growth potential and demand for innovative solutions.

Norlase's business model is based on the sale of its innovative laser devices. By offering portable, efficient, and user-friendly solutions, Norlase has positioned itself as a leader in the ophthalmic laser technology market.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2014
Headquarters
Ballerup, Denmark
Employees
73
Open positions
None listed
Dealroom signal
85.4/100
Industry
Health
Sub-industry
Medical Devices
Sector
Health Tech & Medtech, Laser Technology, Spinout, Nordic Rising Star 2022, Climate Efficiency, Eitclimatecleantech, Seal of Excellence EC, Horizon Europe, DT and LS
Technology
Hardware, Deep Tech
Business model
Manufacturing
Client focus
b2b

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBT✓Debt Feb 2025 $22M — European Investment Bank ↗
GROWTH EQUITY VC✓Equity / VC Jun 2023 $11M — West Hill Capital ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Norlase website traffic

Latest recorded traffic for Norlase is 8.2K monthly website visits, down 48.8% over the last three months. Norlase's team grew 9% over the past year.

Latest monthly visits8.2K 3-month web change-48.8% 1-year team growth+9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Horizon 2020 FET (Future and Emerging Technologies)
  • Innovation Fund Denmark
  • European Innovation Council

Series B and later3 investors entered at this stage

  • Nordic Secondary Fund
  • West Hill Capital
  • European Investment Bank

Other known investors4 additional known investors

  • Technical University of Denmark
  • London BioScience Innovation Centre
  • Market Maturation Fund
  • Niels Korsholm
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇩🇰 Denmark78.3%
🇺🇸 United States16.7%
🇩🇪 Germany3.3%
🇨🇦 Canada1.7%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Norlase on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Norlase’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.